United States
Polyclonal Antibody to TRAIL (human) (CT)
| PSC-1113-C020 | 20 µg | 87.00 USD |  |
||
| PSC-1113-C100 | 100 µg | 369.00 USD | |
||
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand (CD95L) of the TNF family through their death domain containing receptors, TNF-R1 and Fas (CD95). A novel member in the TNF family was identified and designated TRAIL (for TNF-related apoptosis-inducing ligand) and Apo-2L (for Apo-2 ligand) [1,2]. TRAIL is a type II membrane protein and expressed in a variety of human tissues.
|
FIGURES
 Figure: Western blot analysis of TRAIL in HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL (CT) at 1µg/ml.
|
|||||||||||||||||||||||||||||||||||||||||
Product Literature References
A novel receptor for Apo2L/TRAIL contains a truncated death domains: S.A. Marsters, et al.; Curr. Biol. 7, 1003 (1997), Abstract;
An antagonist decoy receptor and a death domain-containing receptor for TRAIL: G. Pan et al.; Science 277, 815 (1997), Abstract;
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors: J.P. Sheridan et al.; Science 277, 818 (1997), Abstract;
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain: M.A. Degli-Esposti, et al.; Immunity 7, 813 (1997), Abstract;
The receptor for the cytotoxic ligand TRAIL: G. Pan et al.; Science 276, 111 (1997), Abstract;
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB: P. Schneider et al.; Immunity 7, 831 (1997), Abstract;
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family: R.M. Pitti et al.; J. Biol. Chem. 271, 12687 (1996), Abstract; Full Text
Identification and characterization of a new member of the TNF family that induces apoptosis: S.R. Wiley et al.; Immunity 3, 673 (1995), Abstract;
another CS2 website
©2018 Axxora, LLC.,
